SCHEMBL4793373

SCHEMBL4793373

Brc1cncc(-c2cc(N(CCc3c[nH]c4ccccc34)N(CCc3c[nH]c4ccccc34)c3cc(-c4cncc(Br)c4)nc(-c4ccccn4)n3)nc(-c3ccccn3)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
GPR84 Q9NQS5 2/20 0.41
CDK4 P11802 6/20 0.41
CCND1 P24385 6/20 0.41
PTPN1 P18031 1/20 0.39
CDK2 P24941 2/20 0.38
HTR1A P08908 2/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
GBA1 P04062 1/20 0.37
HTR6 P50406 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GSK3B P49841 1/20 0.36
NEK4 P51957 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
EIF2AK2 P19525 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771700 0.82 ALDH1A1 (0.51) ALDH1A1GLACDK4CCND1CDK2
SCHEMBL3727648 0.73 ALDH1A1 (0.48) ALDH1A1GLACDK4CCND1CDK2
SCHEMBL2235936 0.72 GBA1 (0.52) ALDH1A1GLACDK4CCND1CDK2
SCHEMBL2240377 0.71 GBA1 (0.47) ALDH1A1GLACDK4CCND1CDK2
SCHEMBL3714461 0.70 CDK4 (0.52) ALDH1A1GPR84CDK4CCND1CDK2
SCHEMBL11968310 0.70 GBA1 (0.49) ALDH1A1GLAGPR84CDK4CCND1
SCHEMBL3962080 0.70 CDK4 (0.58) ALDH1A1CDK4CCND1CDK2GBA1
SCHEMBL2235885 0.70 KMT2A (0.47) ALDH1A1CDK4CCND1CDK2GBA1
SCHEMBL2239320 0.70 KMT2A (0.47) ALDH1A1CDK4CCND1CDK2GBA1
SCHEMBL2240341 0.67 CDK4 (0.50) ALDH1A1GPR84CDK4CCND1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed